This company listing is no longer active
Clover Biopharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Clover Biopharmaceuticals's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 12.7% annually.
Información clave
-16.2%
Tasa de crecimiento de los beneficios
-13.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.0% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | -2,329.7% |
| Margen neto | -258,830.4% |
| Última actualización de beneficios | 30 Jun 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Clover Biopharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -665 | 317 | 996 |
| 31 Mar 23 | 0 | -1,559 | 364 | 1,230 |
| 31 Dec 22 | 0 | -2,452 | 410 | 1,465 |
| 30 Sep 22 | 0 | -4,145 | 428 | 1,757 |
| 30 Jun 22 | 0 | -5,838 | 446 | 2,048 |
| 31 Mar 22 | 0 | -5,927 | 396 | 1,937 |
| 31 Dec 21 | 0 | -6,016 | 346 | 1,826 |
| 31 Dec 20 | 0 | -913 | 76 | 228 |
Ingresos de calidad: 2197 is currently unprofitable.
Margen de beneficios creciente: 2197 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 2197 is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
Acelerando crecimiento: Unable to compare 2197's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 2197 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Rentabilidad financiera
Alta ROE: 2197 has a negative Return on Equity (-2329.68%), as it is currently unprofitable.